C4XD is guided by a Board with extensive expertise in drug discovery and development, clinical trials, transactions and fundraising. The team is detailed below.

Eva-Lotta Allan

Eva‐Lotta has more than 30 years' experience in the healthcare industry. During this time, she has been a senior executive and Board member at both public and private companies. Most recently, Eva‐Lotta was Chief Business Officer (and previously a Board member) at Immunocore, where she held full responsibility for all aspects of business development and played an instrumental role in the $320 million fundraising in 2015. Prior to this, Eva‐Lotta served as Chief Business Officer and member of the Executive Committee and Euronext IPO team for Ablynx NV, as well as senior positions at Vertex Pharmaceuticals (Europe) Ltd, Oxford Asymmetry International plc, Oxford Glycosciences and Amersham International.

Eva-Lotta currently serves as Non-Executive Director and member of the Corporate Governance Committee and the R&D Sub-Committee of Oslo listed company, Targovax ASA and is a Non-Executive Director and member of the dermatology commission of Almirall, Crescendo Biologics and Aleta Biotherapeutics. Eva-Lotta was a Board Member of the UK BioIndustry Association (BIA).

For information on the role of the Board click HERE.